Home / Comparisons / Wegovy vs Ozempic: Same Drug, Different Labels
Wegovy vs Ozempic: Same Drug, Different Labels
Wegovy and Ozempic both contain semaglutide but have different FDA labels. What each is approved for, which trials fit each, and what that means.
On this page
Two names, one active ingredient. What differs is the label: who each product is approved for, and which trials fit which label. Brand names are used here only to identify the FDA labels.
Key takeaways
- Wegovy and Ozempic both contain semaglutide. They are separate FDA-approved products with separate labels.
- Wegovy’s label is built around weight, heart risk and liver disease. It covers long-term weight management, fewer major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and a type of fatty liver disease (MASH).
- Ozempic’s label is built around type 2 diabetes. It covers blood sugar control, fewer major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and kidney outcomes in adults with type 2 diabetes and chronic kidney disease.
- Ozempic has no weight-loss indication on its label. Wegovy’s label does not list blood sugar control.
- Both carry the same boxed warning for thyroid C-cell tumors seen in rodents.
- A compounded version is neither product. FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.
Are Wegovy and Ozempic the same drug?
They share an active ingredient, semaglutide, and both are GLP-1 receptor agonists. They are not the same product. Each was approved through its own application and has its own label (Wegovy injection, NDA 215256; Wegovy tablets, NDA 218316; Ozempic injection, NDA 209637).
Why that matters: a label states the uses that FDA approved for that product. FDA says that before a drug is approved, a company must submit clinical data and show it is safe and effective for its intended uses, and that using an approved drug for an unapproved use is called off-label. An indication on one label does not carry over to the other.
Two details about the forms. Wegovy’s label covers both an injection and tablets (Wegovy label). Ozempic injection has its own label (Ozempic label). Ozempic tablets share a label with Rybelsus, another oral semaglutide product for type 2 diabetes (label for Rybelsus and Ozempic tablets). In this guide, “Ozempic” means the injection unless we say otherwise. Dosing is set by each label and your prescriber; this guide does not give doses.
What is each one approved for?
✓ means the use is listed on that product’s label as worded. — means it is not.
| Use on the label | Wegovy | Ozempic |
|---|---|---|
| Long-term weight management in adults with obesity, or overweight plus a weight-related condition, and, for the injection only, in children 12 and older with obesity | ✓ | — |
| Noncirrhotic MASH with moderate to advanced liver fibrosis (F2–F3), under accelerated approval | ✓ | — |
| Blood sugar control in adults with type 2 diabetes | — | ✓ |
| Reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease | — | ✓ |
The cardiovascular indications are not the same group of people, so we keep them out of the table:
- Wegovy: reducing major cardiovascular events (cardiovascular death, non-fatal heart attack or stroke) in adults with established cardiovascular disease and either obesity or overweight.
- Ozempic: reducing major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. The label for Ozempic tablets words its cardiovascular indication for adults with type 2 diabetes who are at high risk for these events.
Sources: the Wegovy label and the Ozempic label. The MASH indication is under accelerated approval, which the Wegovy label says may be contingent on a confirmatory trial.
Which trials fit which label?
These are randomized trials in people whose characteristics match the labeled uses. We did not read the clinical-studies sections of the labels, so we match trials to labels by who was studied, not by what the label says it relied on. Results are averages.
| Label | Trial | Who was studied | What happened |
|---|---|---|---|
| Wegovy: weight | STEP 1 | 1,961 adults with overweight or obesity, no diabetes, 68 weeks | Average weight change −14.9% vs −2.4% on placebo |
| Wegovy: heart events | SELECT | 17,604 adults with cardiovascular disease and overweight or obesity, no diabetes; mean follow-up 39.8 months | Major cardiovascular events in 6.5% vs 8.0% (HR 0.80, 95% CI 0.72–0.90) |
| Wegovy: liver disease | Phase 3 MASH trial | Adults with MASH and moderate or advanced fibrosis | Fibrosis improved without worsening steatohepatitis in 36.8% vs 22.4%; weight −10.5% vs −2.0% |
| Ozempic: kidney | FLOW | Adults with type 2 diabetes and chronic kidney disease | Composite kidney outcome HR 0.76 (95% CI 0.66–0.88); cardiovascular death HR 0.71 |
What this table does not cover: the trials behind Ozempic’s blood sugar and cardiovascular indications. We did not review them for this guide. Nor did we find, in what we reviewed, a head-to-head trial of the two products.
Two points about reading these side by side:
- The weight and heart trials enrolled people without diabetes. STEP 1 and SELECT excluded diabetes, so they do not tell you what happens in type 2 diabetes. FLOW is in people with type 2 diabetes and kidney disease.
- SELECT’s result applies to people who already had cardiovascular disease. It does not show that semaglutide lowers heart-attack risk in everyone who wants to lose weight.
Can Ozempic be used for weight loss, or Wegovy for diabetes?
Neither is a use on that product’s label as worded, which makes it off-label. That is a decision for a prescriber, and we do not recommend either way. Two things to keep in mind:
- FDA’s evaluation of benefits and risks covers the approved use (FDA).
- The weight-loss results in our guides come from trials of the weight-management product’s population. We did not review a trial of Ozempic for weight loss.
Do they carry the same warnings?
Both labels carry a boxed warning: in rodents, semaglutide caused thyroid C-cell tumors, and it is not known whether either product causes them in humans. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 (MEN 2), and in people with a serious prior hypersensitivity reaction to semaglutide (Wegovy, Ozempic).
One difference we can point to: the Wegovy label says concomitant use of Wegovy with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. We did not compare the two labels’ other warnings line by line; our semaglutide guide lists the Wegovy label’s warnings and the observational findings on a rare eye condition.
Is compounded semaglutide the same as Wegovy or Ozempic?
No. FDA says compounded drugs are not reviewed for safety, effectiveness or quality before they are marketed. It has also reminded telehealth companies not to describe a compounded drug as “clinically proven to produce the same result as the FDA-approved drug” and that FDA does not approve or license any facility. FDA also says it may consider a compounded product that combines semaglutide with vitamin B12 to be essentially a copy of an approved drug in some circumstances. See what FDA says about compounded GLP-1 drugs.
What should you ask your doctor?
- Which label does my reason for treatment fit: weight and heart risk, or type 2 diabetes and its complications?
- If a product is suggested for a use that isn’t on its label, what is the reason and what evidence supports it for me?
- Do I have a personal or family history of medullary thyroid carcinoma or MEN 2? (It rules semaglutide out.)
- Is the product I am being given the approved one or a compounded one? Who makes it?
We do not give doses, and we do not recommend products, pharmacies or sellers.
Frequently asked questions
Is Ozempic the same as Wegovy?
They contain the same active ingredient, semaglutide, but they are separate products with different labels and different approved uses.
Is Ozempic approved for weight loss?
We found no weight-loss indication on Ozempic’s label. Wegovy’s label covers weight management.
Is Wegovy approved for type 2 diabetes?
We did not find blood sugar control among the uses on Wegovy’s label. Ozempic’s label covers it.
Can you use Wegovy and Ozempic together?
The Wegovy label says concomitant use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. Ask your prescriber about your own situation.
Which one works better?
They are approved for different uses, and we did not find a head-to-head trial of the two products, so there is no direct answer. Compare each against its own label and trials.
From Best Peptides Today
Sources we checked
- Wegovy prescribing information, injection and tablets (DailyMed, rev. 06/2026)FDA. Accessed .
- Ozempic prescribing information (DailyMed, version effective June 2026)FDA. Accessed .
- Rybelsus and Ozempic tablets prescribing information (DailyMed, rev. 01/2026)FDA. Accessed .
- Drugs@FDA: NDA 215256 (Wegovy injection)FDA. Accessed .
- Drugs@FDA: NDA 218316 (Wegovy tablets)FDA. Accessed .
- Drugs@FDA: NDA 209637 (Ozempic injection)FDA. Accessed .
- FDA: understanding unapproved use of approved drugs ("off label")FDA. Accessed .
- STEP 1 trial (PubMed)PubMed. Accessed .
- SELECT trial (PubMed)PubMed. Accessed .
- Phase 3 trial of semaglutide in MASH (PubMed)PubMed. Accessed .
- FLOW trial (PubMed)PubMed. Accessed .
- FDA clarifies policies for compounders as national GLP-1 supply stabilizesFDA. Accessed .
- FDA: telehealth companies and promoting compounded drugsFDA. Accessed .
Written and maintained by the Best Peptides For Editorial Team. How we rate evidence.